[en] The functional significance of extracellular signal-regulated kinase 2 (ERK2) activation was investigated during shear induced human platelet aggregation (SIPA) in vitro and during shear controlled thrombosis in vivo in intestinal arterioles and venules of wild type (WT) and transgenic (TG) mice with platelet-specific overexpression of human P2X(1) (TG). The conclusions are that P2X(1) and ERK2 both participate in shear stress controlled thrombosis, but ERK2 activation is initiated predominantly via GPIb-VWF interactions.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Oury, Cécile ; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Daenens, Kim; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Hu, Hu; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Toth-Zsamboki, Emese; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Bryckaert, Marijke; Hopital Lariboisière Paris > U689 INSERM
Hoylaerts, Marc F; Katholieke Universiteit Leuven - KUL > Molecular and Cellular Medicine > CMVB
Language :
English
Title :
ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X.
Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003; 102: 449-61.
Barstad RM, Orvim U, Hamers MJ, Tjonnfjord GE, Brosstad FR, Sakariassen KS. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost 1996; 75: 827-32.
Rao AK. Congenital disorders of platelet function: Disorders of signal transduction and secretion. Am J Med Sci 1998; 316: 69-76.
Hoylaerts MF, Oury C, Toth-Zsamboki E, Vermylen J. ADP receptors in platelet activation and aggregation. Platelets 2000; 11: 307-9.
Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carmeliet P. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7: 215-21.
Dogne JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, Kolh P, Damas J, David JL, Masereel B. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev 2001; 19: 87-96.
Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 (Suppl. 1): 1-6.
Gachet C. Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 2001; 74: 375-81.
Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 2001; 85: 303-8.
van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 2003; 23: 518-23.
Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-83.
Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
Lenain N, Freund M, Leon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost 2003; 1: 1144-9.
Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, Hoylaerts MF. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 2003; 101: 3969-76.
Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198: 661-7.
Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002; 100: 2499-505.
Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J Biol Chem 2003; 278: 46661-7.
Oury C, Sticker E, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation. J Biol Chem 2004; 279: 26266-73.
Mazharian A, Roger S, Maurice P, Berrou E, Popoff MR, Hoylaerts MF, Fauvel-Lafeve F, Bonnefoy A, Bryckaert M. Differential involvement of ERK2 and p38 in platelet adhesion to collagen. J Biol Chem 2005; 280: 26002-10.
Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 1999; 94: 3800-5.
Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 2002; 531: 475-82.
Falker K, Lange D, Presek P. ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets. Thromb Haemost 2004; 92: 114-23.
Rettinger J, Schmalzing G, Damer S, Muller G, Nickel P, Lambrecht G. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. Neuropharmacology 2000; 39: 2044-53.
Jacobson KA, Mamedova L, Joshi BV, Besada P, Costanzi S. Molecular recognition at adenine nucleotide (p2) receptors in platelets. Semin Thromb Hemost 2005; 31: 205-16.
Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001; 86: 1264-71.
Glenn JR, White AE, Johnson A, Fox SC, Behan MW, Dolan G, Heptinstall S. Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood. Platelets 2005; 16: 159-70.
Bonnefoy A, Yamamoto H, Thys C, Kito M, Vermylen J, Hoylaerts MF. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood 2003; 101: 1375-83.
Appeldoorn CC, Bonnefoy A, Lutters BC, Daenens K, van Berkel TJ, Hoylaerts MF, Biessen EA. Gallic acid antagonizes P-selectin-mediated platelet-leukocyte interactions: Implications for the French paradox. Circulation 2005; 111: 106-12.
Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C. Inhibition of platelet functions and thrombosis through selective or non selective inhibition of the platelet P2 receptors with increasing doses of Nf449. J Pharmacol Exp Ther 2005; 314: 232-43.
Li Z, Xi X, Du X. A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3. J Biol Chem 2001; 276: 42226-32.
Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
Ni H, Yuen PS, Papalia JM, Trevithick JE, Sakai T, Fassler R, Hynes RO, Wagner DD. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci USA 2003; 100: 2415-9.
Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 2004; 556: 227-35.
Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, Hoylaerts MF. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002; 99: 4486-93.
Marshall SJ, Senis YA, Auger JM, Feil R, Hofmann F, Salmon G, Peterson JT, Burslem F, Watson SP. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood 2004; 103: 2601-9.
Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost 1998; 79: 202-10.